Table S1.
Flow cytometric analysis of Annexin V-FITC in Jurkat cells after treatment with ZER-NLC
| Cell condition | Cells (%)
|
|||||||
|---|---|---|---|---|---|---|---|---|
| 6 hours
|
12 hours
|
24 hours
|
48 hours
|
|||||
| Control | ZER-NLC | Control | ZER-NLC | Control | ZER-NLC | Control | ZER-NLC | |
| Viable cells | 96.93±0.188 | 79.2±0.16 | 96.39±0.25 | 21.71±0.66 | 93.88±0.16 | 15.48±0.73 | 93.16±0.98 | 28.62±0.94 |
| Early apoptosis | 1.67±0.11 | 12.34±0.51* | 1.85±0.07 | 63.08±0.48* | 3.45±0.11 | 21.37±0.42* | 3.91±0.54 | 12.15±0.40* |
| Late apoptosis/necrosis | 1.39±0.14 | 8.45±0.65** | 1.76±0.2 | 15.19±0.12** | 2.66±0.11 | 63.14±0.58** | 2.92±0.44 | 59.34±1.10** |
Notes: Values are expressed as the mean ± standard deviation of three different experiments. The data were analyzed using post hoc comparison test-one way analysis of variance, and the means were compared by Tukey’s b test.
*
Significant (P<0.05) increase in early apoptotic cells in ZER-NLC-treated group versus untreated control.
**
Significant (P<0.05) increase in late apoptotic/necrotic cells in ZER-NLC-treated group versus untreated control.
Abbreviations: FITC, fluorescein isothiocyanate; ZER-NLC, zerumbone-loaded nanostructured lipid carrier.